Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
about
Levofloxacin prophylaxis in patients with newly diagnosed myeloma (TEAMM): a multicentre, double-blind, placebo-controlled, randomised, phase 3 trial
description
scientific article published on 23 October 2019
@en
name
Levofloxacin prophylaxis in pa ...... led, randomised, phase 3 trial
@en
type
label
Levofloxacin prophylaxis in pa ...... led, randomised, phase 3 trial
@en
prefLabel
Levofloxacin prophylaxis in pa ...... led, randomised, phase 3 trial
@en
P2093
P1433
P1476
Levofloxacin prophylaxis in pa ...... led, randomised, phase 3 trial
@en
P2093
Anand Lokare
Beth Harrison
Claire T Hulme
David Meads
Edward Belsham
Gavin Campbell
Gulnaz Iqbal
Helen Dignum
P304
P356
10.1016/S1470-2045(19)30506-6
P577
2019-10-23T00:00:00Z